On August 12th, the A-share market's concept stocks for COVID-19 treatment rose collectively, among which, Cosunter Pharmaceutical surged by the daily limit of 20%, Staidson went up over 15%, Tianjin Chase Sun Pharmaceutical rose over 13%, Shijiazhuang Yiling Pharmaceutical and Shandong Xinhua Pharmaceutical rose by 10% and 7% respectively, Guangdong Zhongsheng Pharmaceutical was close to the daily limit, Shanxi C&Y Pharmaceutical Group rose more than 8%, and ABA Chemicals Corporation, Tianjin Tasly Pharmaceutical and Shanghai Kaibao Pharmaceutical rose nearly 7%, 7% and 6%, respectively. In terms of news, the World Health Organization warned recently that the infection rate of COVID-19 is soaring worldwide, and the situation is unlikely to improve soon. The international community should pay attention to the abnormal increase in COVID-19 infections during the summer. The WHO said that data from sentinel surveillance systems in 84 countries showed that the percentage of positive COVID-19 tests has been increasing in recent weeks. Currently, the global positive detection rate for COVID-19 is slightly higher than 10%, and it is over 20% in Europe. The WHO also expressed concern that more serious COVID-19 variants may appear soon and recommended that the highest-risk groups be vaccinated against COVID-19. On August 8th, the Chinese Center for Disease Control and Prevention released the situation of new coronavirus infections in July 2024. The proportion of influenza and other virus infections decreased, while the number and proportion of new coronavirus infections increased during the summer. The data showed that the COVID-19 positivity rate among influenza-like cases across the country has been on the rise, from 8.9% from July 1st to July 7th to 18.7% from July 22nd to July 28th. The main prevalent strains are currently Omicron variants, while the main variants in China are the JN.1 and XDV series.